Trial · NCT07887230
iLITE, Clinical Performance of the Angiolite™ Drug-Eluting Stent
NCT07887230, Not yet recruiting, iVascular S.L.U.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. iLITE, Clinical Performance of the Angiolite™ Drug-Eluting Stent. Trials, record NCT07887230. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07887230
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- iLITE, Clinical Performance of the Angiolite™ Drug-Eluting Stent
- NCT number
- NCT07887230
- Status
- Not yet recruiting
- Enrollment
- 5,000 participants, estimated
- Lead sponsor
- iVascular S.L.U.
- Conditions
- PCI Patients, de Novo Coronary Lesions, Restenotic Coronary Lesions, Acute Myocardial Infarction (AMI), Suspected Acute Coronary Occlusion
- Interventions
- Percutaneous Coronary Intervention
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Target Lesion Failure (TLF) | 1 year | TLF defined according to ARC-2 as the composite of cardiovascular death (CVD) target vessel myocardial infarction (TV-MI) and clinically driven (CD) target lesion revascularization (TLR) at 1-year. |
| Secondary | Target Vessel Failure | 1 year | TVF as composite of CVD, TV-MI, Target vessel revascularization (TVR) |
| Secondary | Target Lesion Failure | 2, 3, 4 and 5 years | TLF as composite of CVD, TV-MI, CD TLR at 2, 3, 4 and 5 years based on the data from the first 1,000 patients. |
| Secondary | Patient Oriented Composite endpoint | 1 year | (POCE), composite of any death, any MI and any coronary artery revascularization |
| Secondary | Rate of Periprocedural Myocardial Infarction | Within 48 hours after the index procedure | Percentage of participants with periprocedural myocardial infarction (MI) related to the index PCI procedure, defined according to the Academic Research Consortium-2 (ARC-2) criteria: in patients with normal baseline cardiac troponin (cTn), a post-procedural rise in cTn ≥35 times the 99th percentile upper reference limit (URL), plus at least one of the following: new pathological Q waves, angiographic evidence of a flow-limiting complication (e.g., loss of patency of a major epicardial vessel or side branch, persistent slow flow/no-reflow, embolization), or imaging evidence of new loss of viable myocardium. In patients with elevated baseline cTn, a further rise of \>20% with an absolute post-procedural value ≥35× URL is required. Cardiac troponin is measured at baseline and at 6 and 24 hours post-procedure |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07887230
GET https://conductscience.org/api/trials/v1/NCT07887230/registered